COMMUNIQUÉS West-GlobeNewswire

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
22/09/2026
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic [...]
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
22/09/2026
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a [...]
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
22/09/2026
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a [...]
Lymphatic Malformation Alliance (LMA) Meets with FDA Leadership to Elevate Awareness of Lymphatic Malformations and Advance the Urgent Need for Approved Treatments
22/09/2026
LMA brings patient and physician perspectives to FDA leadership to elevate awareness of lymphatic malformations Patient experience highlights the serious, lifelong burden and significant unmet need LMA calls for greater [...]
Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
22/09/2026
IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet [...]
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
22/09/2026
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider [...]
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
22/09/2026
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a [...]
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
22/09/2026
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that [...]
CorVel Expands Managed Care Connectivity with the CareMC® Extension for Guidewire ClaimCenter
22/09/2026
FORT WORTH, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a national provider of risk management and healthcare solutions, today announced the availability of its Care MC Accelerator for [...]
OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
22/09/2026
WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
22/09/2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – – Additional analyses will assess glucocorticoid-associated toxicity and [...]
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
22/09/2026
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage [...]
Transactions in connection with share buy-back program
22/09/2026
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Bavarian Nordic – Notification of Holding of Treasury Shares
22/09/2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965, [...]
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson's disease
22/09/2026
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson's disease by targeting restorative sleep mechanisms Parkinson's UK-funded research with University College London ( [...]
Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysis
22/09/2026
Silkothane® Arteriovenous Graft is a novel hybrid arteriovenous graft engineered to integrate into patients’ vessels and provide a safe, easy-to-cannulate, durable, vascular access for hemodialysis in patients with end- [...]
Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a
22/09/2026
SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis Positive Phase 1 results strengthen confidence in OPT101 , [...]
HighLife Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe
22/09/2026
Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round . [...]
HighLife lève plus de 90 millions de dollars pour lancer son étude pivot aux États-Unis et accélérer son développement commercial en Europe
22/09/2026
Paris, France - le 22 septembre 2026 – HighLife SAS, Medtech spécialisée dans les solutions transcathéter destinées au traitement des maladies cardiaques structurelles, annonce aujourd’hui avoir réalisé avec succès une [...]

Pages